Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CET

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
03:01p ABBOTT : Hosts Conference Call for Fourth-Quarter Earnings
12/15 ABBOTT : Raising Quarterly Dividend for 46th Straight Year
12/15 ABBOTT LABORATORIES : New implantable heart monitor shares data with patient's s..
12/14 ABBOTT LABORATORIES : Research Conducted at Abbott Laboratories Has Provided New..
12/13 ABBOTT LABORATORIES : $34,809 Federal Contract Awarded to Abbott Laboratories
12/12 WALKER & DUNLOP : America First Investment Advisors Has Increased By $309,984 It..
12/08 ABBOTT LABORATORIES : Q-- Altoona/Butler/Wilmington VAMC Chemistry/Immunoassay A..
12/08 ABBOTT LABORATORIES : $3.82 Million Federal Contract Awarded to Abbott Laborator..
12/07 ABBOTT LABORATORIES : Researchers Submit Patent Application, "Container", for Ap..
12/07 ABBOTT LABORATORIES : ' Trademark Application for "PEDIALYTE SINGLES" Filed
More news
News from SeekingAlpha
12/15 Abbott raising quarterly dividend
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 I'm Sticking With CVS And Walgreens, My Last Two Losers
12/12 Premarket analyst action - healthcare
Financials ($)
Sales 2017 27 184 M
EBIT 2017 6 008 M
Net income 2017 2 227 M
Debt 2017 19 729 M
Yield 2017 1,93%
P/E ratio 2017 47,11
P/E ratio 2018 35,09
EV / Sales 2017 4,28x
EV / Sales 2018 3,77x
Capitalization 96 603 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 62,0 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES44.49%96 603
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386